Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Connect Biopharma Holdings Limited CNTB
$1.19
+$0.04 (3.48%)
На 18:04, 12 мая 2023
+26.05%
Потенциал через год
Ключевые показатели
-
Marketcap
64673410.00000000
-
week52high
2.08
-
week52low
0.56
-
Revenue
-
P/E TTM
0
-
Beta
-0.53521600
-
EPS
-2.37000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 апр 2023 г. в 20:05
Описание компании
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
GlobeNewsWire
06 февр 2023 г. в 08:30
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hosting one-on-one meetings, at the following conferences in February and March 2023:
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
GlobeNewsWire
19 дек 2022 г. в 08:00
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023.
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
GlobeNewsWire
27 окт 2022 г. в 16:05
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or hosting one-on-one meetings at the following upcoming investor and scientific conferences:
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
GlobeNewsWire
03 окт 2022 г. в 16:10
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4
Connect Biopharma Is A Sleeper Heading Into October Data Readout
Seeking Alpha
26 сент 2022 г. в 00:13
The stock is down 80% year-to-date due to disappointing study results from the company's two lead product candidates, CBP-201 and CBP-307. CBP-307 development has been put on ice.